Evolution of Cancer, Adaptive Immunity, and Immunotherapy
DOI:
https://doi.org/10.30683/1927-7229.2019.08.04Keywords:
Adaptive immunity, CD4 T cells, CD8 T cells, CTLA-4, Darwinism, Evolution, Immune-related adverse events, Immunotherapy, Passive immunity, PD-1.Abstract
The first clinical trials to investigate the efficacy of immunotherapy in cancer were problematic because of issues related to product availability, cost, and purity. Moreover, these factors could have contributed to the modest efficacy of these agents. The ability to clone specific genes coupled with the development of recombinant DNA technology removed some major barriers such that only 20 years later, approval of the first engineered monoclonal antibody (mAb) for clinical use occurred with practice-changing implications. Subsequent to rituximab, more than 30 additional mAbs have indications for a number of hematologic malignancies and solid tumors. Indeed, the application of adaptive immunity is now an integral component of therapy for many cancers. This paper delves into the complex science of immunology by investigating how the term evolution is applicable to tumorigenesis, the adaptive immune response, and cancer therapy.
References
Siegel, Rebecca L., Kimberly D. Miller and Ahmedin Jemal. 2019. “Cancer Statistics, 2019.” CA: A Cancer Journal for Clinicians 69(1):7-34. https://doi.org/10.3322/caac.21551 DOI: https://doi.org/10.3322/caac.21551
Hanahan, Douglas and Robert A. Weinberg. 2000. “The Hallmarks of Cancer.” Cell 100(1):57-70. https://doi.org/10.1016/S0092-8674(00)81683-9 DOI: https://doi.org/10.1016/S0092-8674(00)81683-9
Hanahan, Douglas and Robert A. Weinberg. 2011. “Hallmarks of Cancer: The Next Generation.” Cell 144(5):646-74. https://doi.org/10.1016/j.cell.2011.02.013 DOI: https://doi.org/10.1016/j.cell.2011.02.013
Chen, Fei, Xuegian Zhuang, Liangyu Lin, Pengfei Yu, Ying Wang, Yufang Shi, Guohong Hu and Yu Sun. 2015. “New Horizons in Tumor Microenvironment Biology: Challenges and Opportunities.” BMC Medicine 13, Article number:45. https://doi.org/10.1186/s12916-015-0278-7 DOI: https://doi.org/10.1186/s12916-015-0278-7
Wang, Jianlian, Zhongyun Zhao, Beth Barber, Beth Sherrill, Marc Peeters and Jeffrey Wiezorek. 2011. “A Q-TWiST Analysis Comparing Panitumumab Plus Best Supportive Care (BSC) with BSC Alone in Patients with Wild-Type KRAS Metastatic Colorectal Cancer.” British Journal of Cancer 104(12):1848-53. https://doi.org/10.1038/bjc.2011.179 DOI: https://doi.org/10.1038/bjc.2011.179
Ahmed, Nisar, Sam Ahmedzai, Vandana Vora, Sophie Harrison and Silvia Paz. 2004. “Supportive Care for Patients with Gastrointestinal Cancer.” Cochrane Database for Systematic Reviews 3:CD003445. https://doi.org/10.1002/14651858.CD003445.pub2 DOI: https://doi.org/10.1002/14651858.CD003445.pub2
Rao, Uma N.M., Sandra J. Lee, Weixui Luo, Martin C. Mihm Jr. and John M. Kirkwood. “Presence of Tumor-Infiltrating Lymphocytes and a Dominant Nodule Within Primary Melanoma are Prognostic Factors for Relapse-free Survival of Patients with Thick (T4) Primary Melanoma: Pathologic Analysis of the E1690 and E1694 Intergroup Trials.” 2010. American Journal of Clinical Pathology 133(4):646–53. https://doi.org/10.1309/AJCPTXMEFOVYWDA6 DOI: https://doi.org/10.1309/AJCPTXMEFOVYWDA6
Schalper, Kurt A., Jason Brown, Daniel Carvajal-Hausdorf, Joseph McLaughlin, Vamsidhar Velcheti, Konstantinos N. Syrigos, Roy S. Herbst and David L. Rimm. 2015. “Objective Measurement and Clinical Significance of TILs in Non-Small Cell Lung Cancer.” Journal of the National Cancer Institute 107(3):1-9. https://doi.org/10.1093/jnci/dju435 DOI: https://doi.org/10.1093/jnci/dju435
Eriksen, Ann C., Flemming B. Sørensen, Jan Lindebjerg, Henrik Hager, René dePont Christensen, Sanne Kjær-Frifeldt,* and Torben F. Hansen. 2018. “The Prognostic Value of Tumor-Infiltrating Lymphocytes in Stage II Colon Cancer. A Nationwide Population-Based Study.” Translational Oncology 11(4):979-87. https://doi.org/10.1016/j.tranon.2018.03.008 DOI: https://doi.org/10.1016/j.tranon.2018.03.008
Melichar, Bohuslav, Hana Študentova, Hana Kalabova, Denisa Vitaskova, Pavla Čermakova, Helena Hornychova and Ales Ryska. 2014. “Predictive and Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients with Breast Cancer Treated with Neoadjuvant Systemic Therapy.” Anticancer Research 34(3):1115-25.
Cheon, HyeonJoo, Ernest C. Borden and George R. Stark. 2014. “Interferons and Their Stimulated Genes in the Tumor Microenvironment.” Seminars in Oncology 41(2):156-73. https://doi.org/10.1053/j.seminoncol.2014.02.002 DOI: https://doi.org/10.1053/j.seminoncol.2014.02.002
Liu, Chengwen, Yanyan Lou, Gregory Lizée, Hong Qin, Shujuan Liu, Brian Rabinovich, Grace J. Kim, Yi-Hong Wang, Yang Ye, Andrew G. Sikora, Willem W. Overwijk, Yong-Jun Liu, Gang Wang and Patrick Hwu. 2008. “Plasmacytoid Dendritic Cells Induce NK Cell-Dependent, Tumor Antigen-Specific T Cell Cross-Priming and Tumor Regression in Mice.” Journal of Clinical Investigation 118(3):1165-75. https://doi.org/10.1172/JCI33583 DOI: https://doi.org/10.1172/JCI33583
Pace, Luigia, Sara Vitale, Beatrice Dettori, Cecilia Palombi, Valentina La Sorsa, Filippo Belardelli, Enrico Proietti and Gino Doria. 2010. “APC Activation by IFN-α Decreases Regulatory T Cell and Enhances Th Cell Functions.” Journal of Immunology 184:5969-79. https://doi.org/10.4049/jimmunol.0900526 DOI: https://doi.org/10.4049/jimmunol.0900526
Lawrence, Michael S., Petar Stojanov and Paz Polak. 2013. “Mutational Heterogeneity in Cancer and the Search for New Cancer-Associated Genes.” Nature 499:214–18. https://doi.org/10.1038/nature12213 DOI: https://doi.org/10.1038/nature12213
Pennock, Nathan D., Jason T. White, Eric W. Cross, Elizabeth E. Cheney, Beth A. Tamburini and Ross M. Kedl. 2013. “T Cell Responses: Naïve to Memory and Everything in Between. Advances in Physiology Education 37(4):273–83. https://doi.org/10.1152/advan.00066.2013 DOI: https://doi.org/10.1152/advan.00066.2013
Blackburn, Shawn D., Haina Shin, W. Nicholas Haining, Tao Zou, Creg J. Workman, Antonio Polley, Michael R. Betts, Gordon J. Freeman, Dario A. A. Vignali and E. John Wherry. 2009. “Coregulation of CD8+ T Cell Exhaustion by Multiple Inhibitory Receptors During Chronic Viral Infection.” Nature Immunology 10(1):29–37. https://doi.org/10.1038/ni.1679 DOI: https://doi.org/10.1038/ni.1679
Erickson John J., Pavlo Gilchuk, Andrew K. Hastings, Sharon J. Tollefson, Monika Johnson, Melissa B. Downing, Kelli L. Boyd, Joyce E. Johnson, Annette S. Kim, Sebastian Joyce and John V. Williams. 2012. “Viral Acute Lower Respiratory Infections Impair CD8+ T Cells Through PD-1.” Journal of Clinical Investigation 122(8):2967–82. https://doi.org/10.1172/JCI62860 DOI: https://doi.org/10.1172/JCI62860
Leung, Helios T., Jeff Bradshaw, Jeffrey S. Cleaveland and Peter S. Linsley. 1995. “Cytotoxic T Lymphocyte-Associated Molecule-4, a High Avidity Receptor for CD80 and CD86, Contains an Intracellular Localization Motif in Its Cytoplasmic Tail.” Journal of Biological Chemistry 270(42):25107–14. https://doi.org/10.1074/jbc.270.42.25107 DOI: https://doi.org/10.1074/jbc.270.42.25107
Ishida, Yasumasa, Yasutoshi Agata, Keiichi Shibahara and Tasuku Honjo. 1992. “Induced Expression of PD-1, a Novel Member of the Immunoglobulin Gene Superfamily, Upon Programmed Cell Death.” EMBO Journal 11(11):3887-95. https://doi.org/10.1002/j.1460-2075.1992.tb05481.x DOI: https://doi.org/10.1002/j.1460-2075.1992.tb05481.x
Tarhini, Ahmad A., John M. Kirkwood, William E. Gooding, Chao Cai and Sanjiv S. Agarwala. 2007. “Durable Complete Responses With High-Dose Bolus Interleukin-2 In Patients With Metastatic Melanoma Who Have Experienced Progression After Biochemotherapy.” Journal of Clinical Oncology 25(25):3802-07. https://doi.org/10.1200/JCO.2006.10.2822 DOI: https://doi.org/10.1200/JCO.2006.10.2822
Hodi, Frank Stephen, Vanna Chiarion-Sileni, Rene Gonzalez, Jean-Jacques Grob, Piotr Rutkowski, Charles Lance Cowey, Christopher D. Lao, Dirk Schadendorf, John Wagstaff, Reinhard Dummer, Pier Franscesco Ferrucci, Smylie Michael, Andrew Hill, David Hogg, Ivan Marquez-Rodas, Joel Jiang, Jasmine Rizzo, James Larkin and Jedd D. Wolchok. 2018. “Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab Alone in Advanced Melanoma (CheckMate 067): 4-Year Outcomes of a Multicentre, Randomised, Phase 3 Trial.” Lancet Oncology 19(11):1480-92. https://doi.org/10.1016/S1470-2045(18)30700-9 DOI: https://doi.org/10.1016/S1470-2045(18)30700-9
Wan, Yisong Y. and Richard A. Flavell. 2007. “Regulatory T Cells, Transforming Growth Factor–β, and Immune Suppression.” Proceedings of the American Thoracic Society 4(3):271–6. https://doi.org/10.1513/pats.200701-020AW DOI: https://doi.org/10.1513/pats.200701-020AW
Rosser, Elizabeth C. and Claudia Mauri. 2015 “Regulatory B Cells: Origin, Phenotype, and Function.” Immunity 42(4):607-12. https://doi.org/10.1016/j.immuni.2015.04.005 DOI: https://doi.org/10.1016/j.immuni.2015.04.005
Nakamura, Tsukasa and Hidetaka Ushigome. “Myeloid-Derived Suppressor Cells as a Regulator of Immunity in Organ Transplantation.” International Journal of Molecular Sciences 19(8):2357. https://doi.org/10.3390/ijms19082357 DOI: https://doi.org/10.3390/ijms19082357
Park, Min-Jung, Sung-Hee Lee, Eun-Kyung Kim, Eun-Jung Lee, Jin-Ah Baek, Sung-Hwan Park, Seung-Ki Kwok and Mi-La Cho. “Interleukin-10 Produced by Myeloid-Derived Suppressor Cells is Critical for the Induction of Tregs and Attenuation of Rheumatoid Inflammation in Mice.” Scientific Reports 8(1):3753. https://doi.org/10.1038/s41598-018-21856-2 DOI: https://doi.org/10.1038/s41598-018-21856-2
Rapoport, Bernardo Leon, Ronwyn van Eeden, Vincent Sibaud, Joel B. Epstein, Jean Klastersky, Matti Aapro, Devan Moodle. 2017. “Supportive Care for Patients Undergoing Immunotherapy.” Supportive Care in Cancer 25(10):3017-30. https://doi.org/10.1007/s00520-017-3802-9 DOI: https://doi.org/10.1007/s00520-017-3802-9
Naidoo, Jarushka, Daniel T. Page, Bob T. Li, Louise C. Connell, Kaspar Schindler, Mario E. Lacouture, Michael A. Postow and Jedd Wolchok. 2015. “Toxicities of the Anti-PD-1 and Anti-PD-L1 Immune Checkpoint Antibodies.” Annals of Oncology 26(12):2375–91. https://doi.org/10.1093/annonc/mdv383 DOI: https://doi.org/10.1093/annonc/mdv383
Konda, Bhavana, Fadi Nabhan and Manisha Shah. 2017. “Endocrine Dysfunction Following Immune Checkpoint Inhibitor Therapy.” Current Opinion in Endocrinology & Diabetes and Obesity 24(5):337–47. https://doi.org/10.1097/MED.0000000000000357 DOI: https://doi.org/10.1097/MED.0000000000000357
Bernardo, Sebastian, Marina Moskalenko, Michael Pan, Shaily Shah, Serge Sicular, Sara Harcharik, Rui Chang, Philip Friedlander and Yvonne Saenger. 2013. “Elevated Rates of Transaminitis During Ipilimumab Therapy for Metastatic Melanoma.” Melanoma Research 23(1):47–54. https://doi.org/10.1097/CMR.0b013e32835c7e68 DOI: https://doi.org/10.1097/CMR.0b013e32835c7e68
Boutros, Celine, Ahmad Tarhini, Emilie Routier, Olivier Lambotte, Francois Leroy Ladurie, Franck Carbonnel, Hassane Izzeddine, Aurelien Marabelle, Stephane Champiat, Armandine Berdelou, Emilie Lanoy, Matthieu Texier, Cristina Libenciuc, Alexander M. M. Eggermont, Jean-Charles Soria, Christine Mateus and Caroline Robert. 2016.”Safety Profiles of Anti-CTLA-4 and Anti-PD-1 Antibodies Alone and In Combination.” Nature Reviews Clinical Oncology 13(8):473-86. https://doi.org/10.1038/nrclinonc.2016.58 DOI: https://doi.org/10.1038/nrclinonc.2016.58
de Velasco, Guillermo, Youjin Je, Dominick Bossé, Mark M. Awad, Patrick Ott, Raphael B. Moreira, Fabio Schutz, Joaquim Bellmunt, Guru P. Sonpavde, F. Stephen Hodi and Toni K. Choueiri. 2017. “Comprehensive Meta-Analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients.” Cancer Immunology Research 5(4):312–18. https://doi.org/10.1158/2326-6066.CIR-16-0237 DOI: https://doi.org/10.1158/2326-6066.CIR-16-0237
F. Stephen Hodi, Steven J. O'Day, David F. McDermott, Robert W. Weber, Jeffrey A. Sosman, John B. Haanen, Rene Gonzalez, Caroline Robert, Dirk Schadendorf, Jessica C. Hassel, Wallace Akerley, Alfons J.M. van den Eertwegh, Jose Lutzky, Paul Lorigan, Julia M. Vaubel, Gerald P. Linette, David Hogg, Christian H. Ottensmeier, Celeste Lebbé, Christian Peschel, Ian Quirt, Joseph I. Clark, Jedd D. Wolchok, Jeffrey S. Weber, Jason Tian, Michael J. Yellin, Geoffrey M. Nichol, Axel Hoos, and Walter J. Urba. 2010. “Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.” New England Journal of Medicine 363(8):711–23. https://doi.org/10.1056/NEJMoa1003466 DOI: https://doi.org/10.1056/NEJMoa1003466
Wolchok, Jedd D., Bart Neyns, Gerald Linette, Sylvie Negrier, Jose Lutzky, Luc Thomas, William Waterfield, Dirk Schadendorf, Michael Smylie, Troy Guthrie, Jean-Jacques Grob, Jason Chesney, Kevin Chin, Kun Chen, Axel Hoos, Steven J O'Day and Celeste Lebbé. 2010. “Ipilimumab Monotherapy in Patients with Pretreated Advanced Melanoma: A Randomised, Double-Blind, Multicentre, Phase 2, Dose-Ranging Study.” Lancet Oncology 11(2):155–64. https://doi.org/10.1016/S1470-2045(09)70334-1 DOI: https://doi.org/10.1016/S1470-2045(09)70334-1
Sender, Ron, Shai Fuchs, Ron Milo. 2016. “Revised Estimates for the Number of Human and Bacteria Cells in the Body.” PLoS Biology 14(8):e1002533. https://doi.org/10.1371/journal.pbio.1002533 DOI: https://doi.org/10.1371/journal.pbio.1002533
Di Meglio, Paola, Gayathri K. Perera, Frank O. Nestle. 2011. “The Multitasking Organ: Recent Insights into Skin Immune Function.” Immunity 35(6):857–69. https://doi.org/10.1016/j.immuni.2011.12.003 DOI: https://doi.org/10.1016/j.immuni.2011.12.003
Chikuma Shunsuke, Jeffrey A. Bluestone. 2003. “CTLA-4 and Tolerance: The Biochemical Point of View.” Immunology Research 28(3):241–53. https://doi.org/10.1385/IR:28:3:241 DOI: https://doi.org/10.1385/IR:28:3:241
Wing, Kajsa, Yasushi Onishi, Paz Prieto-Martin, Tomoyuki Yamaguchi, Makoto Miyara, Zoltan Fehervari, Takashi Nomura and Shimon Sakaguchi. 2008. “CTLA-4 Control Over Foxp3+ Regulatory T Cell Function.” Science 322(5899): 271-75. https://doi.org/10.1126/science.1160062 DOI: https://doi.org/10.1126/science.1160062
Schmidt, Emily M., Chun Jing Wang, Gemma A. Ryan, Louise E. Clough, Omar S. Qureshi, Margaret Goodall, Abul K. Abbas, Arlene H. Sharpe, David M. Sansom and Lucy S. K. Walker. 2009. “CTLA-4 Controls Regulatory T Cell Peripheral Homeostasis and Is Required for Suppression of Pancreatic Islet Autoimmunity.” Journal of Immunology 182(1):274-82. https://doi.org/10.4049/jimmunol.182.1.274 DOI: https://doi.org/10.4049/jimmunol.182.1.274
Maher, V. Ellen, Laura L. Fernandes, Chana Weinstock, Shenghui Tang, Sundeep Agarwal, Michael Brave, Yang-min Ning, Harpreet Singh, Daniel Suzman, James Xu, Kirsten B. Goldberg, Rajeshwari Sridhara, Amna Ibrahim, Marc Theoret, Julia A. Beaver and Richard Pazdur. 2019. “Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody.” Journal of Clinical Oncology May 22, epub ahead of print. https://doi.org/10.1200/JCO.19.00318 DOI: https://doi.org/10.1200/JCO.19.00318
Postow, Michael A, Robert Sidlow and Matthew D. Hellmann. 2018 “Immune-Related Adverse Events Associated with Immune Checkpoint Blockade.” New England Journal of Medicine 378(2):158–68. https://doi.org/10.1056/NEJMra1703481 DOI: https://doi.org/10.1056/NEJMra1703481
Teulings, Hansje-Eva, Jacqueline Limpens, Sophia N. Jansen, Aeilko H. Zwinderman, Johannes B. Reitsma, Phyllis I. Spuls and Rosalie M. Luiten. 2015. “Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis.” Journal of Clinical Oncology 33(7):773–81. https://doi.org/10.1200/JCO.2014.57.4756 DOI: https://doi.org/10.1200/JCO.2014.57.4756
Horvat, Troy Z., Nelly G. Adel, Thu-Oanh Dang, Kaitlin M. Woo, Katherine S. Panageas, Parisa Momtaz, Michael A. Postow, Margaret K. Callahan, Richard D. Carvajal, Mark A. Dickson, Sandra P. D'Angelo, Jedd D. Wolchok, and Paul B. Chapman. 2015. “Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients with Melanoma Treated with Ipilimumab at Memorial Sloan Kettering Cancer Center.” Journal of Clinical Oncology 33(28):3193-8. https://doi.org/10.1200/JCO.2015.60.8448 DOI: https://doi.org/10.1200/JCO.2015.60.8448
van Wijk, Femke and Hilde Cheroutre. 2010. “Mucosal T Cells in Gut Homeostasis and Inflammation.” Expert Review of Clinical Immunology 6(4):559-66. https://doi.org/10.1586/eci.10.34 DOI: https://doi.org/10.1586/eci.10.34
Asarch, Adam, Orr Barak, Daniel S. Loo and Alice B. Gottlieb. 2008. “Th17 Cells: A New Therapeutic Target in Inflammatory Dermatoses.” Journal of Dermatological Treatment 19(6):318-26. https://doi.org/10.1080/09546630802206660 DOI: https://doi.org/10.1080/09546630802206660
Goods, Brittany A., Amanda L. Hernandez, Daniel E. Lowther, Liliana E. Lucca, Benjamin A. Lerner, Murat Gunel, Khadir Raddassi, Vlad Coric, David A. Hafler and J. Christopher Love. 2017. “Functional Differences Between PD-1+ and PD-1-CD4+ Effector T Cells in Healthy Donors and Patients with Glioblastoma Multiforme.” PLoS ONE 12(9):e0181538. https://doi.org/10.1371/journal.pone.0181538 DOI: https://doi.org/10.1371/journal.pone.0181538
Zinkernagel, Rolf M. and Peter C. Doherty. 1974. “Immunological Surveillance Against Altered Self Components by Sensitised T Lymphocytes in Lymphocytic Choriomeningitis.” Nature 251(5475):547–8. https://doi.org/10.1038/251547a0 DOI: https://doi.org/10.1038/251547a0
Berner, Beate, Davut Akca, Thomas Jung, Gerhard A. Muller and Monika A. Reuss-Borst. 2000. “Analysis of Th1 and Th2 Cytokines Expressing CD4+ and CD8+ T Cells in Rheumatoid Arthritis by Flow Cytometry.” Journal of Rheumatology 27(5):1128-35.
Wong, F. Susan, Jaana Karttunen, Caroline Dumont, Li Wen, Irene Visintin, Ingrid M. Pilip, Nilabh Shastri, Eric G. Pamer and Charles A Janeway Jr. 1999. “Identification of an MHC Class I-Restricted Autoantigen in Type 1 Diabetes by Screening an Organ-Specific cDNA Library.” Nature Medicine 5(9):1026–31. https://doi.org/10.1038/12465 DOI: https://doi.org/10.1038/12465
Babbe, Holger, Axel Roers, Ari Waisman, Hans Lassmann, Norbert Goebels, Reinhard Hohlfeld, Michael Friese, Roland Schröder, Martina Deckert, Stephan Schmidt, Rivka Ravid and Klaus Rajewsky. 2000. “Clonal Expansions of Cd8+ T Cells Dominate the T Cell Infiltrate in Active Multiple Sclerosis Lesions as Shown by Micromanipulation and Single Cell Polymerase Chain Reaction.” Journal of Experimental Medicine 192(3):393–404. https://doi.org/10.1084/jem.192.3.393 DOI: https://doi.org/10.1084/jem.192.3.393
Swain, Susan L., Andrew D. Weinberg and Mike English. 1990. “CD4+ T Cell Subsets. Lymphokine Secretion of Memory Cells and of Effector Cells That Develop From Precursors In vitro.” Journal of Immunology 144(5):1788-99.
Rocken, Michael, Jean-Hilaire Saurat and Christoph Hauser. 1992. “A Common Precursor for CD4+ T Cells Producing IL-2 or IL-4.” Journal of Immunology 148(4):1031-6.
Raphael, Itay, Saisha Nalawade, Todd N. Eagar and Thomas G. Forsthuber. 2015. “T Cell Subsets and Their Signature Cytokines in Autoimmune and Inflammatory Diseases.” Cytokine 74(1):5–17. https://doi.org/10.1016/j.cyto.2014.09.011 DOI: https://doi.org/10.1016/j.cyto.2014.09.011
van Boxel, John A. and Stephen A. Paget. 1975. “Predominantly T-Cell Infiltrate in Rheumatoid Synovial Membranes.” New England Journal of Medicine 293(11):517-20. https://doi.org/10.1056/NEJM197509112931101 DOI: https://doi.org/10.1056/NEJM197509112931101
Banerjee, Subhashis, Carolyn Webber and A. Robin Poole. 1992. “The Induction of Arthritis in Mice by the Cartilage Proteoglycan Aggrecan: Roles of CD4+ and CD8+ T Cells.” Cellular Immunology 144(2):347-57. https://doi.org/10.1016/0008-8749(92)90250-S DOI: https://doi.org/10.1016/0008-8749(92)90250-S
Abbas, Abul K., Kenneth M. Murphy and Alan Sher. 1996. “Functional Diversity of Helper T Lymphocytes.” Nature 383(6603):787-93. https://doi.org/10.1038/383787a0 DOI: https://doi.org/10.1038/383787a0
Hassel, Jessica C., Lucie Heinzerling, Jens Aberle, Oliver Bähr, Thomas K. Eigentler, Marc-Oliver Grimm, Victor Grünwald, Jan Leipe, Niels Reinmuth, Julia K. Tietze, Jörg Trojan, Lisa Zimmer and Ralf Gutzmer. 2017. “Combined Immune Checkpoint Blockade (Anti-PD-1/Anti-CTLA-4): Evaluation and Management of Adverse Drug Reactions.” Cancer Treatment Reviews 57:36–49. https://doi.org/10.1016/j.ctrv.2017.05.003 DOI: https://doi.org/10.1016/j.ctrv.2017.05.003
Alegre Maria L., Helena Shiel, Craig B.Thompson and Thomas F. Gajewski. 1998. “Expression and Function of CTLA-4 in Th1 and Th2 Cells.” Journal of Immunology 161(7):3347–56.
Groux, Hervé, Anne O'Garra, Mike Bigler, Matthieu Rouleau, Svetlana Antonenko, Jan E. de Vries and Maria Grazia Roncarolo. 1997. “A CD4+ T-Cell Subset Inhibits Antigen-Specific T-cell Responses and Prevents Colitis.” Nature 389(6652):737-42. https://doi.org/10.1038/39614 DOI: https://doi.org/10.1038/39614
Foussat, Arnaud, Françoise Cottrez, Valérie Brun, Nathalie Fournier, Jean-Philippe Breittmayer and Hervé Groux. 2003. “A Comparative Study between T Regulatory Type 1 and CD4+CD25+ T Cells in the Control of Inflammation.” Journal of Immunology 171(10):5018-26. https://doi.org/10.4049/jimmunol.171.10.5018 DOI: https://doi.org/10.4049/jimmunol.171.10.5018
Kalekar, Lokesh A. and Daniel L. Mueller. 2017. “Relationship Between CD4 Regulatory T Cells and Anergy In vivo.” Journal of Immunology 198(7):2527-33. https://doi.org/10.4049/jimmunol.1602031 DOI: https://doi.org/10.4049/jimmunol.1602031
Sakaguchi, Shimon, Noriko Sakaguchi, Masanao Asano, Misako Itoh and Masaaki Toda. 1995. “Immunologic Self-Tolerance Maintained by Activated T Cells Expressing IL-2 Receptor Alpha-Chains (CD25). Breakdown of a Single Mechanism of Self-Tolerance Causes Various Autoimmune Diseases.” Journal of Immunology 155(3):1151-64.
Fontenot, Jason D., Marc A. Gavin and Alexander Y. Rudensky. 2003. “Foxp3 Programs the Development and Function of CD4+CD25+ Regulatory T Cells.” Nature Immunology 4(4): 330–6. https://doi.org/10.1038/ni904 DOI: https://doi.org/10.1038/ni904
Bennett, Craig L., Jacinda Christie, Fred Ramsdell, Mary E. Brunkow, Polly J. Ferguson, Luke Whitesell, Thaddeus E. Kelly, Frank T. Saulsbury, Phillip F. Chance and Hans D. Ochs. 2001. “The Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked Syndrome (IPEX) is Caused by Mutations of FOXP3.” Nature Genetics 27(1):20–1. https://doi.org/10.1038/83713 DOI: https://doi.org/10.1038/83713
Zhou, Xuyu, Samantha L Bailey-Bucktrout, Lukas T Jeker, Cristina Penaranda, Marc Martínez-Llordella, Meredith Ashby, Maki Nakayama, Wendy Rosenthal and Jeffrey A Bluestone. 2009. “Instability of the Transcription Factor Foxp3 Leads to the Generation of Pathogenic Memory T Cells In vivo.” Nature Immunology 10(9):1000–7. https://doi.org/10.1038/ni.1774 DOI: https://doi.org/10.1038/ni.1774
Hori, Shohei, Takeshi Takahashi, Shimon Sakaguchi. 2003. “Control of Autoimmunity by Naturally Arising Regulatory CD4+ T Cells.” Advances in Immunology 81:331-71. https://doi.org/10.1016/S0065-2776(03)81008-8 DOI: https://doi.org/10.1016/S0065-2776(03)81008-8
Takahashi, Takeshi, Tomuyuki Tagami, Sayuri Yamazaki, Toshimitsu Uede, Jun Shimizu, Noriko Sakaguchi, Tak W. Mak and Shimon Sakaguchi. 2000. “Immunologic Self-Tolerance Maintained by CD25+CD4+ Regulatory T Cells Constitutively Expressing Cytotoxic T Lymphocyte-Associated Antigen 4.” Journal of Experimental Medicine 192(2):303-10. https://doi.org/10.1084/jem.192.2.303 DOI: https://doi.org/10.1084/jem.192.2.303
Brunet, Jean-François, François Denizot, Marie-Françoise Luciani, Magali Roux-Dosseto, Marie Suzan, Marie-Geneviève Mattei and Pierre Golstein. 1987. “A New Member of the Immunoglobulin Superfamily--CTLA-4.” Nature 328(6127):267–270. https://doi.org/10.1038/328267a0 DOI: https://doi.org/10.1038/328267a0
Chan, Derrick V, Heather Gibson, Barabara M. Aufiero, Adam J. Wilson, Mikehl S. Hafner, Qing-Sheng Mi, Henry K. Wong. 2014. “Differential CTLA-4 Expression in Human CD4+ Versus CD8+ T Cells is Associated with Increased NFAT1 and Inhibition of CD4+ Proliferation.” Genes and Immunity 15(1): 25–32. https://doi.org/10.1038/gene.2013.57 DOI: https://doi.org/10.1038/gene.2013.57
Gattinoni, Luca, Anju Ranganathan, Deborah R. Surman, Douglas C. Palmer, Paul A. Antony, Marc R. Theoret, David M. Heimann, Steven A. Rosenberg and Nicholas P. Restifo. 2006. “CTLA-4 Dysregulation of Self/Tumor-Reactive CD8+ T-Cell Function is CD4+ T-Cell Dependent.” Blood 108:3818–23. https://doi.org/10.1182/blood-2006-07-034066 DOI: https://doi.org/10.1182/blood-2006-07-034066
Hinrichs, Christian S., Rosanne Spolski, Chrystal M. Paulos, Luca Gattinoni, Keith W. Kerstann, Douglas C. Palmer, Christopher A. Klebanoff, Steven A. Rosenberg, Warren J. Leonard and Nicholas P. Restifo. 2008. “IL-2 and IL-21 Confer Opposing Differentiation Programs to CD8+ T Cells for Adoptive Immunotherapy.” Blood 111(11):5326-33. https://doi.org/10.1182/blood-2007-09-113050 DOI: https://doi.org/10.1182/blood-2007-09-113050
Pipkin, Matthew E., Jilian A.Sacks, FernandoCruz-Guilloty, Mathias G.Lichtenheld, Michael J.Bevan, and AnjanaRao. 2010. “Interleukin-2 and Inflammation Induce Distinct Transcriptional Programs that Promote the Differentiation of Effector Cytolytic T Cells.” Immunity 32(1):79–90. https://doi.org/10.1016/j.immuni.2009.11.012 DOI: https://doi.org/10.1016/j.immuni.2009.11.012
Malek, Thomas R. and Iris Castro. 2010. “Interleukin-2 Receptor Signaling: At the Interface Between Tolerance and Immunity.” Immunity 33(2):153–65. https://doi.org/10.1016/j.immuni.2010.08.004 DOI: https://doi.org/10.1016/j.immuni.2010.08.004
Krummel, Matthew F. and James P. Allison. 1996. “CTLA-4 Engagement Inhibits IL-2 Accumulation and Cell Cycle Progression Upon Activation of Resting T Cells.” Journal of Experimental Medicine 183(6):2533–40. https://doi.org/10.1084/jem.183.6.2533 DOI: https://doi.org/10.1084/jem.183.6.2533
Williams, Matthew A., Aaron J. Tyznik and Michael J. Bevan. 2006. “Interleukin-2 Signals During Priming are Required for Secondary Expansion of CD8+ Memory T Cells.” Nature 441(7095):890–3. https://doi.org/10.1038/nature04790 DOI: https://doi.org/10.1038/nature04790
Kwan Tat, Steeve, Marc Padrines, Sandrine Théoleyre, Dominique Heymann, and Yannick Fortun. 2004. “IL-6, RANKL, TNF-alpha/IL-1:Interrelations in Bone Resorption Pathophysiology.” Cytokine Growth Factor Reviews 15(1):49-60. https://doi.org/10.1016/j.cytogfr.2003.10.005 DOI: https://doi.org/10.1016/j.cytogfr.2003.10.005
Aigner, Thomas, Louise McKenna, Alexander Zien, Zhiyong Fan, Pia M. Gebhard and Rlf Zimmer. 2005. “Gene Expression Profiling of Serum- and Interleukin-1β-Stimulated Primary Human Adult Articular Chondrocytes - A Molecular Analysis Based on Chondrocytes Isolated From One Donor.” Cytokine 31(3):227–40. https://doi.org/10.1016/j.cyto.2005.04.009 DOI: https://doi.org/10.1016/j.cyto.2005.04.009
Palmer, Ellen M., Beth C. Holbrook, Subhashini Arimilli, Griffith D. Parks and Martha A. Alexander-Miller. 2010. “IFN-Gamma-Producing, Virus-Specific CD8+ Effector Cells Acquire the Ability to Produce IL-10 as a Result of Entry into the Infected Lung Environment.” Virology 404(2):225–30. https://doi.org/10.1016/j.virol.2010.05.004 DOI: https://doi.org/10.1016/j.virol.2010.05.004
Sun, Jie, Rajat Madan, Christopher L. Karp, Thomas J. Braciale. 2009. “Effector T Cells Control Lung Inflammation During Acute Influenza Virus Infection by Producing IL-10.” Nature Medicine 15(3):277–84. https://doi.org/10.1038/nm.1929 DOI: https://doi.org/10.1038/nm.1929
Trandem, Kathryn, Jingxian Zhao, Erica Fleming and Stanley Perlman. 2011. “Highly Activated Cytotoxic CD8 T Cells Express Protective IL-10 at the Peak of Coronavirus-Induced Encephalitis.” Journal of Immunology 186(6):3642–52. https://doi.org/10.4049/jimmunol.1003292 DOI: https://doi.org/10.4049/jimmunol.1003292
Rainey, Jan K., M. Cynthia Goh. 2002. “A Statistically Derived Parameterization for the Collagen Triple-Helix.” Protein Science 11(11):2748–54. https://doi.org/10.1110/ps.0218502 DOI: https://doi.org/10.1110/ps.0218502
Slamon, Dennis J., Brian Leyland-Jones, Steven Shak, Hank Fuchs, Virginia Paton, Alex Bajamonde, Thomas Fleming, Wolfgang Eiermann, Janet Wolter, Mark Pegram, Jose Baselga, and Larry Norton. 2001. “Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2.” New England Journal of Medicine 344(11):783-92. https://doi.org/10.1056/NEJM200103153441101 DOI: https://doi.org/10.1056/NEJM200103153441101
Gianni, Luca, Wolfgang Eiermann, Vladimir Semiglazov, Alexey Manikhas, Ana Lluch, Sergey Tjulandin, Milvia Zambetti, Federico Vazquez, Mikhail Byakhow, Mikhail Lichinitser, Miguel Angel Climent, Eva Ciruelos, Belén Ojeda, Mauro Mansutti, Alla Bozhok, Roberta Baronio, Andrea Feyereislova, Claire Barton and Jose Baselga. 2010. “ Neoadjuvant Chemotherapy with Trastuzumab Followed by Adjuvant Trastuzumab Versus Neoadjuvant Chemotherapy Alone in Patients with HER2-Positive Locally Advanced Breast Cancer (the NOAH Trial): A Randomised Controlled Superiority Trial with a Parallel HER2-Negative Cohort.” Lancet 375(9712):377-84. https://doi.org/10.1016/S0140-6736(09)61964-4 DOI: https://doi.org/10.1016/S0140-6736(09)61964-4
Romond, Edward H., Edith A. Perez, John Bryant, Vera J. Suman, Charles E. Geyer, Jr., Nancy E. Davidson, Elizabeth Tan-Chiu, Silvana Martino, Soonmyung Paik, Peter A. Kaufman, Sandra M. Swain, Thomas M. Pisansky, Louis Fehrenbacher, Leila A. Kutteh, Victor G. Vogel, Daniel W. Visscher, Greg Yothers, Robert B. Jenkins, Ann M. Brown, Shaker R. Dakhil, Eleftherios P. Mamounas, Wilma L. Lingle, Pamela M. Klein, James N. Ingle, and Norman Wolmark. 2005. “Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer.” New England Journal of Medicine.353(16):1673–84. https://doi.org/10.1056/NEJMoa052122 DOI: https://doi.org/10.1056/NEJMoa052122
Piccart-Gebhart, Martine J., Marion Procter, Brian Leyland-Jones, Aron Goldhirsch, Michael Untch, Ian Smith, Luca Gianni, Jose Baselga, Richard Bell, Christian Jackisch, David Cameron, Mitch Dowsett, Carlos H. Barrios, Günther Steger, Chiun-Shen Huang, Michael Andersson, Moshe Inbar, Mikhail Lichinitser, István Láng, Ulrike Nitz, Hiroji Iwata, Christoph Thomssen, Caroline Lohrisch, Thomas M. Suter, Josef Rüschoff, Tamás Sütő, Victoria Greatorex, Carol Ward, Carolyn Straehle, Eleanor McFadden, M. Stella Dolci, and Richard D. Gelber for the Herceptin Adjuvant (HERA) Trial Study Team. 2005. “Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer.” New England Journal of Medicine 353(16):1659–72. https://doi.org/10.1056/NEJMoa052306 DOI: https://doi.org/10.1056/NEJMoa052306
Marcus, Robert, Kevin Imrie , Philippe Solal-Celigny , John V. Catalano , Anna Dmoszynska , João C. RaposoFritz C. Offner , José Gomez-Codina , Andrew Belch , David Cunningham , Elisabeth Wassner-Fritsch and George Stein. 2008. “Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular Lymphoma.” Journal of Clinical Oncology 6(28):4579–86. https://doi.org/10.1200/JCO.2007.13.5376 DOI: https://doi.org/10.1200/JCO.2007.13.5376
Hiddemann, Woflfgang, Michael Kneba, Martin Dreyling, Norbert Schmithz, Eva Lengfelder, Rudolf Schmits, Marcel Reiser, Bernd Metzner, Harriet Harder, Susanna Hegewisch-Becker, Thomas Fischer, Martin Kropff, Hans-Edgar Reis, Mathias Freund, Bernhard Wormann, Roland Fuchs, Manfred Planker, Jorg Schimke, Hartmut Eimermacher, Lorenz Trumper, Ali aldaoud, Reza Parwaresch and Michael Unterhal. 2005. “Frontline Therapy with Rituximab Added to the Combination of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) Significantly Improves the Outcome for Patients with Advanced-Stage Follicular Lymphoma Compared with Therapy with CHOP Alone: Results of a Prospective Randomized Study of the German Low-Grade Lymphoma Study Group.” Blood 106(12):3725–32. https://doi.org/10.1182/blood-2005-01-0016 DOI: https://doi.org/10.1182/blood-2005-01-0016
Salles, Gilles, Nicolas Mounier, Sophie de Guibert, Franck Morschhauser, Chantal Doyen, Jean-Francois Rossi, Corinne Haioun, Pauline Brice, Beatrice Mahe, Reda Bouabdallah, Bruno Audhuy, Christophe Ferme, Caroline Dartigeas, Pierre Feugier, Catherine Sebban, Luc Xerri and Charles Foussard. 2008. “Rituximab Combined with Chemotherapy and Interferon in Follicular Lymphoma Patients: Results of the GELA–GOELAMS FL 2000 Study.” Blood 112(13):4824–31. https://doi.org/10.1182/blood-2008-04-153189 DOI: https://doi.org/10.1182/blood-2008-04-153189
Arnold, Donald M. Francesco Dentali, Mark A. Crowther, Ralph M. Meyer, Richard J. Cook, Christopher Sigouin, Graeme A. Fraser, Wendy Lim and John G. Kelton. 2007. “Systematic Review: Efficacy and Safety of Rituximab for Adults with Idiopathic Thrombocytopenic Purpura.” Annals of Internal Medicine 146(1):25–33. https://doi.org/10.7326/0003-4819-146-1-200701020-00006 DOI: https://doi.org/10.7326/0003-4819-146-1-200701020-00006
Collongues, Nicolas, David Brassat, Emmanuel Maillart, Pierre Labauge, Jean-Christophe Ouallet, Clarisse Carra-Dalliere, Thibault Moreau, Bertrand Bourre, Caroline Papeix, Bruno Brochet, Bertrand Audoin, Sandra Vukusic, Jerome de Seze and Romain Marignier on behalf of the OFSEP and CFSEP. 2016. “Efficacy of Rituximab in Refractory Neuromyelitis Optica.” Multiple Sclerosis 22:955-9. https://doi.org/10.1177/1352458515602337 DOI: https://doi.org/10.1177/1352458515602337
Moja, Lorenzo, Ludovica Tagliabue, Sara Balduzzi, Elena Parmelli, Vanna Pistotti, Valentina Guarneri and Roberto D’Amico. 2012. “Trastuzumab Containing Regimens for Early Breast Cancer.” Cochrane Database of Systematic Reviews (4):CD006243. https://doi.org/10.1002/14651858.CD006243.pub2 DOI: https://doi.org/10.1002/14651858.CD006243.pub2
Feldman, Arthur M., Beverly H. Lorell, Steven E. Reis. 2000. “Trastuzumab in the Treatment of Metastatic Breast Cancer.” Circulation 102:272–4. https://doi.org/10.1161/01.CIR.102.3.272 DOI: https://doi.org/10.1161/01.CIR.102.3.272
Quirke, Phil, Andrew Pickles, Nadia L. Tuzi, Omar Mohamdee and William J. Gullick. 1989. “Pattern of Expression of c-erbB2 Oncoprotein in Human Fetuses.” British Journal of Cancer 60:64-9. https://doi.org/10.1038/bjc.1989.221 DOI: https://doi.org/10.1038/bjc.1989.221
Leandro, Maria J., Geraldine Cambridge, Michael R. Ehrenstein and Jonathan C.W. Edwards. 2006. “Reconstitution of Peripheral Blood B Cells after Depletion with Rituximab in Patients with Rheumatoid Arthritis.” Arthritis and Rheumatology 54(2):613–20. https://doi.org/10.1002/art.21617 DOI: https://doi.org/10.1002/art.21617
Roll, Petra, Thomas Dörner and Hans‐Peter Tony. 2008. “Anti-CD20 Therapy in Patients with Rheumatoid Arthritis: Predictors of Response and B Cell Subset Regeneration after Repeated Treatment.” Arthritis and Rheumatology 58(6):1566–75. https://doi.org/10.1002/art.23473 DOI: https://doi.org/10.1002/art.23473
Pescovitz, Mark D. 2006. “Rituximab, an Anti-cd20 Monoclonal Antibody: History and Mechanism of Action.” American Journal of Transplantion 6(5 Pt 1):859–66. https://doi.org/10.1111/j.1600-6143.2006.01288.x DOI: https://doi.org/10.1111/j.1600-6143.2006.01288.x
Sibilia, Maria, Joachim P. Steinbach, Laura Stingl, Adriano Aguzzi and Erwin F. Wagner. 1998. “A Strain‐Independent Postnatal Neurodegeneration in Mice Lacking the EGF Receptor.” EMBO Journal 17(3):719-31. https://doi.org/10.1093/emboj/17.3.719 DOI: https://doi.org/10.1093/emboj/17.3.719
American Cancer Society. Breast Cancer Facts & Figures 2017-2018. Atlanta: American Cancer Society, Inc. 2019.
Chung, Maureen, Helena R. Chang, Kirby I. Bland and Harold J. Wanebo. 1996. “Younger Women with Breast Carcinoma have a Poorer Pognosis than Older Women.” Cancer 77(1):97-103. https://doi.org/10.1002/(SICI)1097-0142(19960101)77:1<97::AID-CNCR16>3.0.CO;2-3 DOI: https://doi.org/10.1002/(SICI)1097-0142(19960101)77:1<97::AID-CNCR16>3.0.CO;2-3
Anders, Carey K., David S. Hsu , Gloria Broadwater , Chaitanya R. Acharya , John A. Foekens , Yi ZhangYixin Wang , P. Kelly Marcom , Jeffrey R. Marks , Phillip G. Febbo, Joseph R. Nevins , Anil Potti and Kimberly L. Blackwell. 2008. “Young Age at Diagnosis Correlates With Worse Prognosis and Defines a Subset of Breast Cancers With Shared Patterns of Gene Expression.” Journal of Clinical Oncology 26(20):3324–30. https://doi.org/10.1200/JCO.2007.14.2471 DOI: https://doi.org/10.1200/JCO.2007.14.2471
Sivakumar, Poornima, Chandni Ravi and Gabriel Rodrigues. 2015. “Breast Cancer in Young Women: The Effect of Age on Tumor Biology and Prognosis.” Clinical Cancer Investigation Journal 4(2):165-9. DOI: https://doi.org/10.4103/2278-0513.148980
